<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01522586</url>
  </required_header>
  <id_info>
    <org_study_id>DWP09031</org_study_id>
    <nct_id>NCT01522586</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of DWP09031</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose-escalation Clinical Phase 1 Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of DWP09031</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and
      pharmacodynamics of orally administrated DWP09031 in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    change development strategy
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety&amp;tolerability</measure>
    <time_frame>-1d, 0 (predose), 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h, 8d (post-study visit)</time_frame>
    <description>Adverse events, Physical exam, Vital sign, laboratory(CBC,chemistry,U/A etc)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>0 (predose), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 ,24 ,36, 48 h</time_frame>
    <description>Cmax, AUClast, AUCinf, t1/2, CL/F, Vd/F</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>DWP09031</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP09031</intervention_name>
    <description>DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing</description>
    <arm_group_label>DWP09031</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult male subjects aged 20 to 45 years

          2. The subject has Broca's index ≤ 20%

          3. A Subject who was judged to be healthy by the investigator to participate in this
             study based on screening results (according to standard reference index updated
             recently)

          4. A subject who provided written informed consent to participate in this study and
             cooperative with regard to compliance with study related constraints

        Exclusion Criteria:

          1. A subject with sign or symptoms or previously diagnosed disease of liver (viral
             hepatitis), digestive system, cardiovascular, kidney, respiratory, endocrinology,
             neurology, immune system, hematology, and psychology function or other significant
             diseases and history or suspicion of current drug abuse and alcohol abuse

          2. A subject who shows vital signs with the number of systolic blood pressure of ≥141
             mmHg or ≤89 mmHg, and the number of diastolic blood pressure of ≥91mmHg

          3. A subject who shows the following result in clinical laboratory test:

             AST,ALT&gt;1.25 times of the upper limit of normal range PR ≥ 210 msec QRS ≥ 120 msec QT
             ≥ 500 msec QTcF ≥ 450 msec creatinine clearance ≤ 80mL/min

          4. Subject who has taken other clinical or licensed medication from another clinical
             trial within an 90-day period prior to the first administration of the study
             medication (The last administration of the medication is considered as an end point of
             the previous clinical trial).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Gook Shin, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>BUSAN PAIK HOSPITAL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University College of Medicine Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <state>Busanjin-gu</state>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2012</study_first_submitted>
  <study_first_submitted_qc>January 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2012</study_first_posted>
  <last_update_submitted>February 12, 2014</last_update_submitted>
  <last_update_submitted_qc>February 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

